Form 4: Kiniksa Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
John F. Paolini, Chief Medical Officer of Kiniksa Pharmaceuticals, reports acquisition and disposal of Class A Common Shares and Restricted Share Units.
Summary
- On April 1, 2024, John F. Paolini, the Chief Medical Officer of Kiniksa Pharmaceuticals, engaged in transactions involving the company's Class A Common Shares and Restricted Share Units (RSUs).
- Paolini acquired 1,624 Class A Common Shares through the vesting of RSUs.
- He also disposed of 477 Class A Common Shares to cover tax obligations at a price of $19.7 per share.
- Following these transactions, Paolini directly owns 46,039 Class A Common Shares and 4,872 Restricted Share Units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities. It allows investors to monitor the actions of key personnel and their alignment with company performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders by slightly increasing the number of outstanding shares and potentially affecting the stock price, although the effect is likely minimal due to the small volume of shares involved.
Key Dates
| Date | Description |
|---|---|
| 04/01/2023 | Grant date of the Restricted Share Units (RSUs) which vest over a four-year period. |
| 04/01/2024 | Date of the reported transactions: acquisition of shares through RSU vesting and disposal of shares for tax obligations. |
| 04/03/2024 | Date of signature by Attorney-in-Fact for the reporting person. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.